SAB Biotherapeutics (SABS) Long-Term Investments (2021 - 2026)

SAB Biotherapeutics (SABS) posted Long-Term Investments of $110.2 million for Q1 2026, up 135.08% on a QoQ basis from $46.9 million in Q4 2025.

SAB Biotherapeutics (SABS) Long-Term Investments (2021 - 2026) Analysis & Trends

SAB Biotherapeutics' Long-Term Investments history runs 4 years deep, the most recent figure standing at $110.2 million for Q1 2026.

Quarterly Long-Term Investments changed N/A year-over-year to $110.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $110.2 million (changed N/A YoY) and the FY2025 annual result came in at $46.9 million, changed N/A from the prior year.
Long-Term Investments was $110.2 million for Q1 2026 at SAB Biotherapeutics, up from $46.9 million in the prior quarter.
Across five years, Long-Term Investments topped out at $110.2 million in Q1 2026 and bottomed at $1.2 million in Q1 2024.
A 3-year average of $52.2 million and a median of $48.8 million in 2025 frame the typical range for Long-Term Investments.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	505,194.89
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	SAB Biotherapeutics	170.64 Mn	170.64 Mn	-	110.24 Mn

Download Data